MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. Show more

Location: 42 Hayarkon Street, Yavne, 8122745, Israel | Website: https://www.mediwound.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

180.2M

52 Wk Range

$14.14 - $22.50

Previous Close

$16.57

Open

$16.42

Volume

80,917

Day Range

$16.39 - $16.99

Enterprise Value

155.8M

Cash

32.44M

Avg Qtr Burn

-3.815M

Insider Ownership

17.86%

Institutional Own.

44.70%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.